Logo

Lilly Signs Agreement with Ypsomed to Advance an Automated Insulin Delivery System for People with Diabetes

Share this

Lilly Signs Agreement with Ypsomed to Advance an Automated Insulin Delivery System for People with Diabetes

Shots:

  • In terms of the agreement- lilly will commercialize the system- which is currently in development & will include an insulin pump developed & manufactured by ypsomed
  • Ypsomed's insulin pump has been marketed in europe since 2016- available in 21 countries as the mylife ypsopump. Lilly will commercialize a version of this insulin pump- along with CGM & automated insulin delivery technology- in the US & europe also this pump will use pre-filled insulin cartridges for Lilly's rapid-acting insulins
  • Ypsomed plans to submit a version of the mylife ypsopump for clearance to the US FDA for use in automated insulin delivery in 2022- if cleared- lilly will have exclusive rights to commercialize the pump in the US

 ­ Ref: Lilly | Image: Lilly

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions